Wednesday, October 29, 2025
- 11:45AM-12:00PM
-
Abstract Number: 2670
Real-World Experience of Anifrolumab in 24 Patients with Refractory Dermatomyositis: A Multicenter Retrospective Study.
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I: Diagnostics & Therapeutics (2669–2674)- 11:45AM-12:00PM
-
Abstract Number: 2658
Risk of Immune-Mediated Inflammatory Diseases and Other Safety Outcomes in Patients with T2DM and Obesity Initiating GLP-1 RA: A Propensity Score-Matched Multi-center Study using the TriNetX Global Network
Abstracts: Epidemiology & Public Health I (2657–2662)- 11:45AM-12:00PM
-
Abstract Number: 2688
Single cell RNA-seq immune profiling of blood samples from a psoriatic disease clinical trial reveals a CD4 T cell population associated with response to IL-23 blockade
Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions (2687–2692)- 11:45AM-12:00PM
-
Abstract Number: 2676
Tofacitinib in Juvenile spondyloarthropathy: clinical efficacy, impact on biomarkers and comparison with Adalimumab
Abstracts: Pediatric Rheumatology – Clinical III (2675–2680)- 12:00PM-12:15PM
-
Abstract Number: 2683
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Abstracts: Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes III: Long Live (Comorbidity and Outcomes) (2681–2686)- 12:00PM-12:15PM
-
Abstract Number: 2695
B-cell depletion and lymphoid follicle disruption upon different B-cell depleting agents
Abstracts: Systemic Lupus Erythematosus – Treatment II (2693–2698)- 12:00PM-12:15PM
-
Abstract Number: 2689
Comparison of Incidence of Psoriatic Arthritis in Patients With Psoriasis Treated With Interleukin-17 Inhibitors vs Interleukin-23 Inhibitors, Interleukin-12/23 Inhibitors, and Tumor Necrosis Factor Inhibitors in Real-World Practice: A Retrospective Study
Abstracts: Spondyloarthritis Including Psoriatic Arthritis – Treatment II: Pathogenesis, Exercise, and Dietary Interventions (2687–2692)- 12:00PM-12:15PM
-
Abstract Number: 2671
Effect of Efgartigimod PH20 SC on Total Improvement Score, its Core Set Measures, and Patient/Clinician Impressions of Change: Results from the Phase 2 ALKIVIA Study of Adults with Active Idiopathic Inflammatory Myopathy
Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I: Diagnostics & Therapeutics (2669–2674)- 12:00PM-12:15PM
-
Abstract Number: 2701
Ophthalmic Manifestations of Relapsing Polychondritis
Abstracts: Vasculitis – Non-ANCA-Associated & Related Disorders II (2699–2704)- 12:00PM-12:15PM
-
Abstract Number: 2665
Preexisting Antibodies Against Vaccine Antigens Are Preserved In Patients With Systemic Lupus Erythematosus and Sjögren’s Disease Upon Ianalumab Treatment While Autoantibodies Decline
Abstracts: Miscellaneous Rheumatic & Inflammatory Diseases III: End Organ Focus on Heart, Lung and Eye (2663–2668)- 12:00PM-12:15PM
-
Abstract Number: 2677
Quantified Imaging Response at the Sacroiliac Joints to TNF-Inhibitor Therapy in Youth with Axial Disease
Abstracts: Pediatric Rheumatology – Clinical III (2675–2680)- 12:00PM-12:15PM
-
Abstract Number: 2659
Sodium-Glucose Cotransporter 2 Inhibitors for the Primary Prevention of Systemic Autoimmune Rheumatic Diseases in Patients with Type 2 Diabetes: A Population-Based Target Trial Emulation
Abstracts: Epidemiology & Public Health I (2657–2662)- 12:15PM-12:30PM
-
Abstract Number: 2696
Biomarker Data From an Open-Label, Phase 1/2 Study for YTB323 (Rapcabtagene Autoleucel, a Rapidly Manufactured CD19 CAR-T Therapy) Suggest Reset of the B Cell Compartment in Severe Refractory SLE
Abstracts: Systemic Lupus Erythematosus – Treatment II (2693–2698)- 12:15PM-12:30PM
-
Abstract Number: 2702
Diagnostic Performance of Vascular Ultrasound in Giant Cell Arteritis – A Single Center Experience